Nichole Tucker

In season 4, episode 11 of Targeted Talks, Krisda Chaiyachati, MD, MPH, MSHP, discusses the social determinants of health for patients with cancer and key challenges for patients, like transportation insecurity.

Treatment has been initiated in a phase 1/2 study of TNG260 added to pembrolizumab in patients with advanced or metastatic solid tumors.

In an interview with Targeted Oncology, Mitul Gandhi, MD, reviewed the latest guideline recommendations for the workup and treatment of acute myeloid leukemia.

According to Bradley J. Monk, MD, FACS, FACOG, et al, multiple studies have shown the potential of tisotumab vedotin in patients with recurrent or metastatic cervical cancer. More evidence is needed before the oncology community can fully adopt its use.

Primary results from the phase 1 COVALENT 101 study demonstrate the potential of BMF-219 to induce responses in patients with various relapsed or refractory leukemias/lymphomas, including acute myeloid leukemia.

In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.

Results from a subgroup analysis of the phase 3 SIENDO study show a survival advantage, signaling that tp53 may have predictive value for treatment with selinexor, in addition to its prognostic value.

In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.

In an interview with Targeted Oncology, Omid Hamid, MD, discussed the efficacy of fianlimab in combination with cemiplimab for advanced melanoma. The results of the study show new possibilities for treating patients who have failed adjuvant anti PD-1 therapy.

The Data Monitoring Committee for the phase 3 KEYNOTE-A18 clinical trial has announced that the study met one of its primary end points.

In an interview with Targeted Oncology™, Q2 2023 Oncology Icons honoree, Thaddeus Beck, MD, FACP, discussed his 30 plus years of experience in clinical practice.

Phase 3 research is underway to explore the efficacy and safety of selinexor plus ruxolitinib for the treatment of myelofibrosis in adults.

PAPILLON represents the first randomized study of newly-diagnosed patients with EGFR exon 20-mutant non–small cell lung cancer to show clinically meaningful results.

In an interview with Targeted Oncology, Hope S. Rugo, MD, explained the results of the phase 3 CAPItello-291 trial, and the potential impact of the study on the breast cancer treatment paradigm.

In an interview with Targeted Oncology, Q2 2023 Oncology Icons honoree, Tara Graff, DO, MS, discusses her path to community oncology from academia, and hopes to continue to advance community-based research in the future.

In an interview with Targeted Oncology, Manmeet S. Ahluwalia, MD, a Q2 2023 Oncology Icons honoree, looks back on the career moves that led him to this award, including his work at Cleveland Clinic, the ASCO Leadership Development Program, and Baptist Health South Florida.

In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.

The phase 1b/2 ASP-1929-181 continues to investigate the photoimmunotherapy, ASP-1929, in combination with anti-EGFR therapy in patients with advanced head and neck cancer and other solid tumors.

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

A further look at nivolumab combined with cisplatin-based chemotherapy outside of the primary CheckMate-901 study shows survival benefit for the study combination.

In the phase 3 TIGeR-PaC study, intra-arterial administration of gemcitabine demonstrated positive progression-free and overall survival outcomes in patients with locally advanced pancreatic cancer.

An investigation of treatment with concurrent paxalisib and whole brain radiotherapy is underway in a phase 1 clinical trial.

The FDA plans to conduct a speedy review of an approval application for zolbetuximab in first-line locally advanced, unresectable, or metastatic HER2-negative, claudin18.2-positive gastric or gastroesophageal junction adenocarcinoma.

An investigation of selective targeting of A2AR in patients with certain solid tumors is underway in a first-in-human study.

Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer.

According to investigators of the phase 3 HIMALAYA trial, updated findings confirm the role of the STRIDE regimen in the unresectable hepatocellular carcinoma treatment paradigm.

In an interview with Targeted Oncology, Nicholas Girard, MD, PhD reviews 3 key abstracts presented at the ELCC 2023, in which different targeted therapies were administered to patients with EGFR-mutant non–small cell lung cancer in clinical trial and real-world settings.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Treatment with the investigational drug FHD-286 exhibits positive results in patients with metastatic uveal melanoma and will be explored further in acute myeloid leukemia and myelodysplastic syndrome.

The phase 2b VIRAGE study will investigate the safety and efficacy of VCN-01 plus standard chemotherapy in patients with first-line pancreatic ductal adenocarcinoma.